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1. INTRODUCTION 
 
1.1. Genomic instability  
The maintenance of genomic stability is essential for cellular integrity (1). 
Genomic instability includes small structure variations such as increased frequencies of base pair 
mutation, microsatellite instability (MSI), as well as significant structure variation such as 
chromosome number or structure changes, which is also called chromosome instability (2,3). 
Double-strand breaks (DSBs) are one of the most dangerous types of DNA damage because they 
disrupt the continuity of chromosomes (4,5). Failure to eliminate DSBs leads to genome 
instability and tumorigenesis (4,6). DSBs are predominantly repaired by either the non-
homologous end-joining (NHEJ) pathway or the homologous recombination (HR) pathway (7,8). 
NHEJ directly ligates the broken DNA ends, whereas HR uses a homologous sequence from 
sister chromatid as a repair template (7,9). 
Correct repair of DSBs is critical for the maintenance of genome stability. HR and NHEJ are the 
two dominant repair pathways involved in DSB repair (7,9). 
 
 
1.1.1. Genome instability and cancer 
 
A high rate of changes to a cell's genome enables the acquisition and evolution of the well-
known hallmarks of cancer. As such, virtually all cancer cells exhibit genomic instability in one 
form or another. For example, at least two thirds of human cancers are mosaic aneuploid as a 
result of frequent gains and losses of whole chromosomes during cell divisions. Such whole-
chromosomal instability (wCIN) can promote gains of extra copies of oncogenes or losses of 
tumour-suppressor genes, and it allows the selection of karyotypes that thrive in certain 
environments. Tumor relapse following the initial success of anticancer therapies, as well as 
anticancer drug resistance, has therefore been attributed to wCIN (10) . 
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Another form of genomic instability frequently observed in cancer cells is instability at the level 
of chromosome structure. Structural CIN (sCIN) encompasses a variety of changes to the 
genome, including translocations, deletions, inversions, and fragmentations. sCIN is caused by a 
poor repair of damaged DNA, due to, for example, mutations in DNA repair pathway 
components or inefficient cellular responses to DNA damage (11). 
 
 
1.1.2. Genome instability, cancer and micronucleus 
 
Almost 100 years ago, Theodor Boveri introduced a hypothesis mechanistically linking 
chromosomal abnormalities to carcinogenesis (12). As a result of his observations, a causal role 
of these events in anetiology of cancers has been postulated. 
Cancer is a genomic disease associated with accumulation of genetic damage. The majority of 
solid tumours show a large number of complex chromosomal aberrations (CAs) that are not 
always shared by cells of the same tumour and may be not necessarily linked to a particular 
tumour type (13). These chromosomal alterations occur in benign and malignant lesions, as well 
as in pre-neoplastic stages, and include structural and numerical aberrations. The acquisition of 
genomic instability, a condition that predisposes a cell to accumulate stable genome mutations, 
represents an early step in the process of carcinogenesis (14). 
Cellular genomes are continuously exposed to endogenous and exogenous insults causing 
structural alterations to chromosomes leading to altered gene dosage and expression. Mutations 
in oncogenes, tumour suppressor genes and other genes involved in genome maintenance could 
therefore lead to a mutator phenotype that increases the risk of acquiring new mutations 
including those associated with cancer (15). 
The most frequently observed errors in cancer cell lines are chromosomes that lag behind the 
separating packs of chromosomes at anaphase (16). These laggards can acquire damage during 
cytokinesis, resulting in deletions and chromosomal translocations in daughter cells (17). These 
and other types of missegregated chromosomes also form micronuclei, structures often used as a 
marker in cancer diagnosis. Micronuclei suffer from replication stress and damage (18). 
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Several human syndromes, including Fanconi anaemia, Bloom’s syndrome, Werner’s syndrome, 
ataxia, telangiectasia and others, characterised by heritable mutations in a variety of tumour 
suppressor genes have been associated with a chromosomal instability and cancer predisposition  
(19). Epidemiological studies of cancer risk in first-degree relatives of cases have consistently 
shown a 2- to 3-fold increased risk over the general population, and selection for early-onset 
cases generally produces a higher relative risk (20,21). Over 100 Mendelian cancer syndromes, 
including hereditary breast/ovarian cancer, familial adenomatous polyposis, hereditary non-
polyposis colon cancer and von Hippel–Lindau syndrome are all known to involve deficiencies 
in DNA repair systems, but they only account for 5% of cancer cases (19). The cancer risk 
modulation in the general population principally involves genes of low or moderate penetrance 
that, in combination, are responsible for the observed interindividual cancer susceptibility (19). 
Micronucleus (MN) and other nuclear anomalies such as nucleoplasmic bridges (NPBs) and 
nuclear buds (NBUDs) are biomarkers of genotoxic events and manifestations of chromosomal 
instability that are often seen in cancer (22).  
 
 
1.1.3. The origin of micronucleus  
It is now well-established that MN mainly originate from acentric chromosome fragments, 
acentric chromatid fragments or whole chromosomes (Figure 1) that fail to be included in the 
daughter nuclei at the completion of telophase during mitosis, because they did not attach 
properly with the spindle during the segregation process in anaphase (23-26). 
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Figure 1. Micronucleus formation adopted from Luzhna L et al. (27). 
 
Micronucleus from acentric chromosome or chromatid fragments 
Acentric chromosome fragments originate via multiple mechanisms. Radiation biology studies 
over several decades have shown that misrepair of DNA double-strand breaks can lead to 
symmetrical and asymmetrical chromatid and chromosome exchanges as well as chromatid and 
chromosome fragments (23-26). A small proportion of acentric chromosome fragments may 
simply arise from unrepaired double-stranded DNA breaks, but this is only likely when DNA 
damage load exceeds the repair capacity of the cell within a specified time frame. The propensity 
for misrepair of DNA breaks is enhanced if the error-free homologous recombinational DNA 
repair pathway is dysfunctional due to defects in relevant genes such as BRCA1 and BRCA2; 
  5 
 
furthermore, DNA breaks, which lead to MN formation, may be left unrepaired if repair enzymes 
in the non-homologous end joining pathway are defective (28,29). 
Other mechanisms that could lead to MN formation from acentric fragments include 
simultaneous excision repair of damaged (e.g. 8-oxo-deoxyguanosine) or inappropriate bases 
incorporated in DNA (e.g. uracil) that are in proximity and on opposite complementary DNA 
strands. Such simultaneous excision repair events, particularly if the gap-filling step is not 
completed, leads to DNA double-strand breaks and MN formation (30,32). In fact, this process 
can be exploited to greatly enhance the lymphocyte MN assay response to genotoxic agents that 
mainly induce DNA adducts. This enhanced sensitivity is achieved by converting excision-
repairable DNA lesions into DNA strand breaks, and therefore, MN by treatment with cytosine 
arabinoside (during G1 phase of the cell cycle), which inhibits the gap-filling step of excision 
repair (33). More recently, it has been shown that MN can also originate from fragmented 
chromosome material when NPB are formed, stretched and broken during telophase (34). 
Micronucleus from malsegregated whole chromosomes 
Lymphocyte MN in healthy people, not abnormally exposed to genotoxins, usually originate 
from either acentric chromosome fragments or whole chromosome loss events at a ratio ranging 
between ∼30:70% at one extreme to 70:30% at the other extreme depending on age and gender. 
In lymphocytes, MN increase with age and are generally higher in females relative to males (25). 
Sex chromosomes contribute the majority of chromosome loss events with increasing age (35).  
There are a range of possible molecular mechanisms that could cause chromosome 
malsegregation at anaphase resulting in MN formation. One of the mechanisms that may lead to 
MN from chromosome loss events is hypomethylation of cytosine in centromeric and 
pericentromeric repeat sequences such as classical satellite repeats at pericentromeric regions 
and higher-order repeats of satellite DNA in centromeric DNA (36,37). Other variables that are 
likely to increase MN from chromosome loss are defects in mitotic spindle assembly, mitosis 
check point defects and abnormal centrosome amplification (38,39). A recent study suggests that 
dicentric chromosomes resulting from telomere end fusions may often be involved in mis-
segregation events; this may occur when the centromeres of the dicentric chromosome are pulled 
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towards opposite poles of the cell during anaphase with forces that are sufficient to detach the 
chromosome from the spindle (40). 
 
1.1.3.1. Micronuclei formation: from genetics to epigenetics 
Epigenetics has become a very promising target for manipulation in molecular biology because 
of the growing evidence of its involvement in chromatin status regulation, gene expression; and 
both epigenetics and genetics have an equal influence on the development of genomic instability 
and cancer (41). The greatest potential of epigenetic alterations is their reversible nature in 
contrast to mutations. 
Epigenetics is rather defined as a memory of stable changes in gene expression without changes 
in gene sequence, and such memory can be passed on to progeny (42). The ability of cells to 
change gene expression without altering gene sequence not only allows for maintaining tissue 
identity but also gives a possibility for the adaptation to a changing environment, should such 
changes occur (43). Because transcription requires the cooperative effort of chromatin, the 
protein complexes that modify chromatin structure and transcription factors, the objective of 
epigenetics is to find out how both the genetic code in the DNA sequence and the way that the 
DNA is packaged control gene expression (44).  
The presence of micronuclei is a hallmark of chromosome instability. Micronuclei are formed 
when one or a few chromosomes fail to join a daughter nucleus and form their own nuclear 
envelope (18).  Micronuclei appear to be structurally comparable to primary nuclei, but display 
reduced functioning in transcription, replication and DNA damage repair (45). These defects are 
likely a consequence of reduced nuclear pore protein levels in micronuclei leading to impaired 
micro-nuclear trafficking (18,34,46). 
Epigenetic regulation includes at least four outlined mechanisms: DNA methylation, histone 
modifications, chromatin remodelling, and non-coding RNA expression (47,48). 
DNA methylation is studied more than others. A methyl group replaces a hydrogen atom in the 
cytosine base of DNA, thus creating a new covalent bond. Such modification happens 
predominantly in cytosine-phosphate-guanine (CpG)-dinucleotides (49). The addition of a 
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methyl group does not affect the transcription of cytosine, but it alters chromatin in a way such 
that to interfere with and reduce DNA-binding capacities of transcription factors (50). Methyl-
CpG-binding proteins (MBPs) recruit transcriptional suppressors to modify chromatin (51,52). 
Enzymes that methylate DNA are DNA methyltransferases: DNMT1, DNMT2, DNMT3a, and 
DNMT3b. DNMT1 can maintain a DNA methylation pattern by reading and faithfully copying it 
from an old DNA strand to a newly synthesized strand during replication. DNMT3a and b target 
unmethylatedCpG sites for de novo methylation in embryonic stem cells and cancer cells (53). 
Such methylation activity is important for the establishment of parental imprints (54). DNMT2 
has been shown to methylate tRNA(55), in addition to a weak methyltransferase activity in 
vitro (56). 
During the past years, it has become clear that DNA damage accumulates in micronuclei (46,57). 
This damage has been suggested to be a starting point for chromothripsis (57), where one or 
multiple chromosomes acquire dozens to hundreds of clustered rearrangements in a single 
catastrophic event (58). Chromothripsis is common in cancer and is associated with poor 
prognosis (58,59). One of the current models for chromothripsis involves DNA shattering in 
micronuclei followed by reincorporation into a daughter nucleus, where random religation can 
take place (60). 
The role of DNA methylation should be emphasized as crucial for normal development and 
genome stability. The distribution of CpG-dinucleotides is not random in the genome. Most of 
CpG sites are clustered in promoter areas of genes creating so-called CpG islands (49). Usually, 
promoters of tumour suppressor genes are hypomethylated to allow their expression for normal 
functioning of cells (61), whereas oncogenes and some repeat elements are silenced through 
hypermethylation, thus maintaining genome integrity (62). Reanimated transposons can lead to 
translocations, gene disruption, and chromosomal instability (63). X chromosome inactivation is 
also a result of hypermethylation (64). Centromeric regions of chromosomes are heterochromatic 
and lay within tandemly repeated DNA. Constitutive heterochromatin of centromeres is 
epigenetically silenced by histone methylation and DNA hypermethylation, thus enabling a low 
frequency of recombination and the repression of transcription (65,66). However, 
undermethylation of repeated DNA sequences and satellite DNA in the centromeric and 
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pericentromeric regions of chromosomes is highly linked to karyotypic instability found in a 
variety of cancers (67). 
The association between folate levels and MN are shown in many papers. Folate is an important 
B group vitamin that partakes in a complex homocysteine cycle which yields SAM – a key 
methyl donor for DNA methyltransferases (68). Some studies have shown that folate deficiency 
is associated with genomic damage and formation of MN and other nuclear abnormalities in 
human lymphocytes (69,70). Furthermore, folate supplementation led to a pronounced reduction 
in DNA damage and MN formation (71). 
Moreover, folate and vitamin B12 perform an important function supplying methyl groups 
essential for DNA metabolism and maintenance (72,73). Folate is required for the synthesis of 
deoxythymidine monophosphate (dTMP) from deoxyuridine monophosphate (dUMP) and plays 
a very important role as a methyl donor within the folate–methionine and DNA methylation 
maintenance pathways (74). It has been shown that both micronutrient deficiency and/or excess 
can have detrimental effects in terms of genome damage (75). In folate deficiency condition, 
dUMP accumulates resulting in uracil being incorporated into DNA instead of thymine (76). 
Excessive incorporation of uracil not only leads to point mutations but also results in single- and 
double-strand DNA breaks, chromosome breakage and MN formation (77,78). 
Vitamin B12 deficiency also causes high uracil incorporation by restricting synthesis of the form 
of folate required for dTMP synthesis (i.e. 5,10 methylenetetrahydrofolate), resulting in 
increased chromosome breakage (72,79). Folate and vitamin B12 are required for the synthesis 
of methionine through the remethylation of homocysteine (HCy) and the synthesis of S-
adenosylmethionine (SAM), the common methyl donor required for the maintenance of 
methylation patterns involving cytosine that determinesgene expression and DNA conformation 
(79,80). 
These data provide additional support to the epigenetic mechanisms of formation of micronuclei. 
Some studies have shown the crucial role of altered histone acetylation in MN formation (81,82). 
Only a few studies indicate that microRNAs (miRNAs) are involved in the induction of MN. 
miRNAs are known to regulate gene silencing in mammals, fish, frogs, insects, worms, flowers, 
and viruses. Approximately 2–3% of the human genome encode for miRNAs are important for 
cellular proliferation, apoptosis, differentiation, tissue and organ developing (83). 
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A study of Aypar et al. showed an immediate induction of MN following radiation exposure 
which was paralleled with alterations in DNA methylation and miRNA expression (41). 
 
 
1.1.3.2. Micronuclei and genotoxic agents 
 
Different cytogeneticists have been studying and describing the genotoxic effect of multiple 
exposures on cells and organisms, relating such exposures to chromosomal aberrations, genomic 
instability, and cancer development (84). The micronucleus formed as a result of clastogenic or 
aneugenic treatment will differ in their content. Thus, clastogens and aneugens will form 
micronucleus with acentric fragments and whole chromosomes, respectively (85). 
Micronuclei testing is widely used for the evaluation of genotoxicity of different anti-cancer 
drugs. Adriamycin is an anthracycline drug with strong mutagenic properties that increases 
micronucleus incidence up to 10- to 15-fold and significantly declines cell survival (86, 87). 
Curcumin alone induces MN in PC12 cells but reduces the total frequency of micronucleus 
induced by cisplatin, thus showing both genotoxic and antigenotoxic properties, depending on 
prescription protocols (88). Similarly, anti-cancer drugs, gemcitabine and topotecan, increase 
abnormal metaphases and the number of micronuclei in mouse bone marrow (89). 
Genome damage including DNA strand breakage, chromosome rearrangement, aneuploidy or 
alterations in methylation patterns and subsequent alterations in gene dosage and gene expression 
have been identified as being fundamental to the development of human diseases, such as cancer 
(72,90). In this context biomarkers of chromosome damage need to be sensitive enough to reflect 
changes within the genome as a result of exposure to exogenous and endogenous agents.  
Except to the drugs mentioned above, MN test has been also used in other drugs: vindesine, an 
anti-mitotic vinca alkaloid, if combined with gamma-radiation, reduces survival of V79 cells by 
increasing the frequency of MN (91). Teniposide, an anti-tumor drug used for treatment of 
childhood acute lymphocytic leukemia, induced MN with a peak frequency at 16 h after 
treatment, which was correlated with cell survival decline (91). An interesting genotoxic 
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mechanism of action of natural alkaloids of pyrido-thiazolo-acridine series was observed; 
acridines acted through the DNA-intercalating mechanism in the dark, but DNA-adducts were 
formed after photo-activation (92). Last but not least, some methylating agents, generated a 
linear dose response in MN formation (93). 
As shown in the paragraphs above, MN frequency has been extensively used as a biomarker to 
measure rates of chromosomal damage within human populations investigating exposure to 
genotoxic agents (94), micronutrient deficiency or excess (73,95), or differences in genotypic 
profiles (96). Micronutrient status plays an important role in the protection against genome 
damage by providing co-factors required for the efficient function of enzymes involved in DNA 
repair, detoxification or maintenance of methylation of the genome (97,98). Micronutrient 
deficiency or excess can have modifying effects on genomic integrity that may involve nutrient–
nutrient or nutrient–gene interactions and may depend on an individual’s genetic constitution 
(99). 
Genotoxicity of the environment and manufactory pollution has always been an important issue 
(100,101). In their study, Neri et al. described the effect of various environmental mutagens on 
the frequency of MN in children (0–18 years). Namely, common genotoxic agents, such as 
ionizing radiation, air pollution, and chemical drugs, cause an increase in MN frequency in 
children (102). 
Hornhardt et al. showed that the combination of arsenic trioxide in the concentration close to that 
occurring in nature induces MN in human lymphoblastoid cells if combined with gamma-
radiation. Similar observations were made for genotoxicity of chelate complexes of mercury (II) 
employed in the detoxification of some polluted areas (103). 
In a series of studies, Dorn et al. evaluated clastogenic and aneugenic effects of various anabolic 
steroids misused by athletes in sports (104). Most of these steroids induced micronucleus in V79 
cells up to 2-fold compared with controls, thus, presenting a potential genotoxic hazard (104). 
The potential hazards of dental adhesives interacting with pulp tissues can also be expected. 
Dental adhesives cause the generation of ROS contributing to MN formation up to 6-fold in V79 
cells (105). 
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Micronucleus  test confirm a slight genotoxic potential of the common ingredient of oxidative 
hair dyes, p-phenylenediamine (PPD), in vitro, but not in vivo (106). 
Because genotoxicity is linked to chromosome aberrations, it is expected that cigarette smoking 
would cause MN. Surprisingly, most studies deny the ability of smoking compounds to induce 
MN. In the Human MicroNucleus project, 1409 current smokers and 800 former smokers were 
tested for MN in lymphocytes. Both groups showed a decrease in MN frequency compared to 
non-smokers (107). Although, when tobacco-specific nitrosamine (NNK) was added to the 
culture of the repair-deficient fibroblasts, the frequency of MN was doubled (108), suggesting 
that smoking could induce MN in repair-deficient cells. 
Multiple studies describe kinetics of MN induction by different genotoxic agents (109). For 
instance, some vinca alkaloids block cell division immediately, while vinblastine and vincristine 
cause a delay after exposure, although producing a higher maximal velocity (110). Continuing to 
discuss genotoxicity, it should be mentioned that the induction of MN by colchicine also occurs 
rapidly; MN-PCE (micronucleated polychromatic erythrocyte) appeared in blood stream almost 
at the same time as after exposure to gamma-rays (111). A long latency period in MN formation 
was observed after methylnitrosourea, thus proving that the agent causes DNA breaks through 
the repair of mismatches induced during a previous division. Therefore, a relationship exists 
between the kinetics of MN and chromosomal break formation (112). 
 Micronuclei formation: lifestyle factors, dietary intervention and genetic polymorphisms 
Different variants may have an impact in the effect of some agents on MN frequency. They are 
host factors, lifestyle (smoking, alcohol, occupation, folate, and vitamins intake), and disease 
susceptibility, cancer, etc. (113). Moreover, multiple studies on MN formation and impact of 
many factors on its formation are done: A vitamin antioxidant combination containing the 
vitamins A, C, E as well as beta-carotene, folic acid and rutin, when taken daily for 4 months, 
reduced gammaradiation- induced MN frequency significantly in both younger and older 
subjects. This is suggestive that antioxidant micronutrient combinations may be effective in 
reducing DNA damage, resulting from both exogenous andendogenous insults (114). 
Epidemiological evidence suggests that a diet-containing phenolic compounds may decrease 
genomic instability by protecting DNA from oxidative damage (115,116). In a study, where 
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individuals were placed on a low polyphenol diet for 48 h prior to the consumption of 300 ml of 
red or white wine, it was shown that plasma collected at time points up to 3 h following wine 
consumption produced a significant 70% reduction in hydrogen peroxide-induced 
MN frequency (117). This suggests that consumption of wine may have a protective effect on 
DNA damage levels. 
Gender factors have been studied related to the MN formation. Mainly, a higher micronucleus 
frequency has been reported for women (118). Similarly, the effect of gender was described for 
MN associated with aneuploidy (centromere-positive MN), which was higher in females (119). 
The frequency of X chromosome loss was also shown to be higher in females, especially in older 
women with X chromosome loss of approximately 22% (120). The impact of alcohol 
consumption on MN formation was also observed(119). The effect of smoking correlated 
linearly with chromosomal aberrations such as sister chromatid exchanges (118), and it 
surprisingly had no influence on MN formation (120). 
Bolognesi et al. described an age-related increase in chromosome damages and MN formation in 
lymphocytes (121). Also,  analysis of population data from 12 Italian laboratories in the mid-
1980s–1990s showed the most dramatic increase in MN in the age group of 50–59 that remained 
unchanged thereafter (121). The age-associated incline in CA and MN may be caused by a 
decline in DNA repair (122) and the aneuploidy phenomenon (123). Genomic instability and 
oncogenicity cause the accumulation of DNA damage with age. Oxidative damage can also 
contribute to MN frequency during ageing (124). The baseline MN frequency in new-borns and 
children is relatively low, but higher susceptibility to DNA damages in children may rapidly 
increase the MN formation due to environmental exposure to genotoxic agents (125).  
Single antioxidant supplements 
Vitamin C acts as both an antioxidant and a pro-oxidant, which in this latter role may involve the 
reduction of DNA-bound anions, such as copper and iron that have the capacity to reduce 
hydrogen peroxide to form the highly reactive hydroxyl radical. Interaction of these hydroxyl 
radicals with the DNA backbone can lead to single- or double-strand breaks leading to MN 
formation (126). Vitamin C in vitro has been shown to increase DNA damage in a dose-
dependent manner and at higher doses to enhance the cytotoxicity of hydrogen peroxide to 
human lymphocytes (127). The anti-oxidant capacity of vitamin C stems from the poor reactivity 
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of the semi-hydroascorbate radical produced upon reaction with reactive oxygen metabolites 
(128). Epidemiological evidence shows that a high intake of vitamin C-rich foods reduces the 
risk of certain cancers by up to 50% (129). 
 
Dual antioxidants 
An intervention study involving cohorts of smokers and non-smokers were supplemented with 
vitamin C and E to investigate the impact on Micronucleus frequency. Baseline concentrations of 
both vitamins were lower in the smokers, who also had higher MN frequency compared to the 
non-smoker cohort. Both cohorts were supplemented with 1000 mg vitamin C daily for 7 days 
and then for a further 7 days with both 1000 mg vitamin C and 335 mg vitamin E. The MN 
frequency was significantly reduced in both cohorts, but was more pronounced in the smoker 
cohort (130). 
A crossover intervention study investigated both the alcoholic and non-alcoholic fraction of wine 
in relation to the potential protective effects against DNA damage induced by oxidative stress 
(131). Similarly, individuals were placed on a low-polyphenol diet for 48 h prior to the 
consumption of 300 ml of complete red wine, de-alcoholised red wine or ethanol on three 
separate occasions 1 week apart. The de-alcoholised wine significantly reduced radiation-
induced MN frequency at 1 and 2 h post-consumption by 20%. Interestingly, the ethanol fraction 
increased radiation-induced DNA damage, whereas the complete wine was more effective in 
reducing MN frequency relative to the ethanol fraction, but was not as effective as the de-
alcoholised wine (131). 
Genetic polymorphisms have the major influence on interindividual susceptibility to MN 
formation (132). Single nucleotide polymorphisms in DNA repair genes XRCC1, XRCC3, and 
XPD (xerodermapigmentosum group D) increased micronucleus frequencies in radiological 
workers exposed to low levels of ionizing radiation compared to control individuals of the same 
genotype (133). Also, glutathione S-transferase M1 polymorphisms influenced MN induction in 
coke oven workers, smokers, and subjects living in polluted areas (134). ALDH2 (aldehyde 
dehydrogenase 2) polymorphism is also associated with micronucleus formation induced by 
alcohol (135). 
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The predisposition for diseases, such as cancer, is correlated with micronucleus frequency. 
MTHFR (methylenetetrahydrofolate reductase) variants involved in folate metabolism may 
develop into coronary artery disease (136). Carriers of BRCA1 and BRCA2 mutations are 
predisposed to enhanced sensitivity to DNA damage, micronucleus formation, and cancer 
development (137). 
Van Leeuwen et al. developed a transcriptomic network analysis of MN-related genes based on 
the knowledge from literature and a case study on children and adults who were differentially 
exposed to air pollution. Using a pathway tool MetaCore, the authors retrieved 27 genes and 
gene complexes involved in MN formation. Such genes were mainly associated with cell cycle 
checkpoints, spindle assembly, and aneuploidy. The network was tested against a gene 
expression case study of individuals living in highly polluted mining area of Teplice in Czech 
Republic and less polluted area of Prachatice in the same country. Six genes from the network 
were combined with p53 and IL-6 to create a micronucleus network (138). 
 
1.1.4. The origin of nucleoplasmic bridge  
NPB originate during anaphase when the centromeres of dicentric chromosomes are pulled to 
opposite poles of the cell during mitosis (Figure 2). In the absence of breakage of the anaphase 
bridge, the nuclear membrane eventually surrounds the daughter nuclei and the anaphase bridge 
and in this manner, an NPB is formed. NPB are usually broken during cytokinesis but they can 
be accumulated in cytokinesis-blocked cells using the cytokinesis inhibitor cytochalasin-B (25). 
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Figure 2. Micronucleus originates from either lagging whole chromosomes or acentric 
chromosome fragments. Nucleoplasmic bridge originates from dicentric chromosomes that 
may be caused by misrepair of double strand DNA breaks or telomere end fusions. These 
events can only be observed in cells completing nuclear division, which are recognized by 
their binuclear cell appearance after cytokinesis blocking with Cyt-B. Adopted from Fenech 
M (25). 
 
 
Dicentric chromosomes originate either from misrepair of chromosome breaks or telomere to 
telomere end fusions (23-26). The two mechanisms of nucleoplasmic bridge formation can be 
distinguished in binucleated cytokinesis-blocked cells using telomere probes. NPB arising from 
telomere end fusions are expected to be telomere positive if they retain telomere sequences 
and/or if the fusions are caused by telomere dysfunction due to loss of telomere-binding proteins 
without telomere attrition; however, if the fusion was caused due to complete erosion of telomere 
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sequence, the NPB originating from such a mechanism can only be recognised with a specific 
probe that hybridises in the subtelomeric region adjacent to the telomeric repetitive sequence 
track (25, 139, 140, 141). In contrast, an NPB caused by misrepair of DNA breaks has a low 
probability of occurring within the telomeric sequences and is therefore likely to be telomere 
negative (25, 26). Furthermore, NPB arising from misrepair of DNA breaks are also likely to be 
associated with an MN originating from the acentric fragment generated during misrepair (26, 
142). 
 
1.1.5. The origin of nuclear bud  
Over the past decades, another unique nuclear anomaly known as nuclear budding has been 
associated with chromosomal instability events. Nuclear buds (NBUDs) have been observed in 
cultures grown under strong selective conditions, which induce gene amplification as well as 
under moderate folic acid deficiency (143,146). Shimizu et al. used in vitro experiments with 
mammalian cells to show that amplified DNA is selectively localised to specific sites at the 
periphery of the nucleus and is eliminated via nuclear budding during S phase of the cell cycle 
(147,148). Amplified DNA may be eliminated from chromosomes through recombination 
between homologous regions within amplified sequences forming mini-circles of acentric and 
atelomeric DNA (double minutes). The NBUDs are characterised by having the same 
morphology as an MN with the exception that they are connected to the nucleus by a narrow or 
wide stalk of nucleoplasmic material depending on the stage of the budding process. The 
duration of the nuclear budding process and the extrusion of the resulting MN from the cell have 
been studied in great detail by time-lapse live-cell imaging techniques (149,150). It is also 
reported that MN may also be formed by a budding process following exposure to γ-irradiation 
HOAF SEG. In this process, Rad 51-recombination protein complexes are detectable throughout 
the entire nucleus 3 h after irradiation and then become concentrated into distinct foci before 
being extruded from the nucleus as NBUD. NBUDs have also been shown to be formed when an 
NPB between two nuclei breaks and the remnants shrink back towards the nuclei (151,152). 
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According to the model proposed by Lindbergh et al. (153) MN in binucleate lymphocytes 
primarily derive from lagging chromosomes and terminal acentric fragments during mitosis; 
however, most NBUDs originate from interstitial or terminal acentric fragments. Such NBUDs 
may possibly represent nuclear membrane entrapment of DNA that has been left in cytoplasm 
after nuclear division or from excess DNA that is being extruded from the nucleus. Whether 
NBUDs are also a mechanism to eliminate excess chromosomes in a hypothesised process 
known as aneuploidy rescue remains unclear as there is only limited evidence for this possibility 
(150,154,155). Micronuclei are cytoplasmatic chromatin masses with the appearance of small 
nuclei that arise from chromosome fragments or intact whole chromosomes lagging behind at the 
anaphase stage of cell division. Their presence is a reflection of structural and/or numerical 
chromosome aberrations arising during mitosis (156). 
 
 
1.2. Premalignant and malignant neoplasms of cervix 
 
No form of cancer better documents the remarkable effects of screening, early diagnosis, and 
curative therapy on mortality rate than does cervical cancer. Fifty years ago, carcinoma of the 
cervix was the leading cause of cancer death in women in the United States, but the death has 
declined by two thirds to its present rank as eighth leading cause of cancer mortality (157). 
Pathogenesis. The pathogenesis of cervical carcinoma has been delineated by a series of 
epidemiologic, clinic pathologic, and molecular genetic studies. Epidemiological data have long 
implicated a sexually transmitted agent, which is now established to be HPV. For his discovery 
of HPV as a cause of cervical cancer, Harald zur Hausen was awarded the Noble Prize in 2008. 
HPVs are DNA viruses that are typed based on their DNA sequence and sub grouped into high 
and low oncogenic risk. High oncogenic risk HPVs are currently considered to be the single most 
important factor in cervical oncogenesis (157). 
HPV infection is recognized (Figure 3) as the necessary cause of cervical intraepithelial lesions 
(CIN) and invasive squamous cell carcinoma (SCC) (158). Virtually all cervical cancers are 
  18 
 
caused by persistent infections with high-risk human papillomavirus (HR-HPV) types which 
may cause cervical intraepithelial neoplasia and invasive cancer (159). 
HR-HPV E6 and E7 oncoproteins are considered essential for the development of cervical cancer 
in persistent HPV lesions by interacting with p53 and pRB tumour suppressor proteins, which 
play an important role in the regulation of normal cell cycle (160). 
An essential prerequisite for the shift from a clinically unapparent transient HPV infection to 
initiation of transformation and maintenance of neoplastic growth of the cell is the continuous 
expression of the viral oncogenes E6 and E7 in basal and parabasal epithelial cells (161). 
 
 
Figure 3. Cervical carcinogenesis. A long-term persistent HPV infection in cervical dysplasia or 
cervical intraepithelial neoplasia (CIN) could possibly lead to cervical cancer by integration of 
viral DNA into the host genome and overexpression of viral genes E6 and E7. Adopted from 
Castillo A (162). 
 
 
There are 15 high oncogenic risk HPVs that are currently identified. From the point of view of 
cervical pathology, HPV 16 and HPV 18 are the most important. HPV 16 alone accounts for 
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almost 60% of cervical cancer cases, and HPV 18 accounts for another 10% of cases; other may 
contribute less than 5% of cases individually (163). 
The risk factors for cervical cancer are to both host and viral characteristics such as HPV 
exposure, viral oncogenicity, inefficiency of immune response, and presence of co-carcinogenes 
(159). These include: 
1. Multiple sexual partners 
2. A male partner with multiple previous or current sexual partners 
3. Young age at first intercourse 
4. High parity 
5. Persistent infection with a high oncogenic risk HPV, e.g. HPV 16 or HPV 18 
6. Immunosuppression 
7. Certain HLA subtypes 
8. Use of oral contraceptives 
9. Use of nicotine 
 
HPVs infect immature basal cells of squamous epithelium or immature metaplastic squamous 
cells present at the squamocolumnar junction. HPVs cannot infect the mature superficial 
squamous cells. Establishing HPV infection in these sites requires damage to the surface 
epithelium, which gives the virus access to the immature cells in the basal of layer of the 
epithelium. Although the virus can infect only the immature squamous cells, replication of HPV 
occurs in the maturing squamous cells and results in a cytopathic effect, “koilocytic atypia’’, 
consisting of nuclear atypia and a cytoplasmic perinuclear halo. Since HPV replicates in 
maturing, non-proliferating squamous cells, it must reactivate the mitotic cycle in such cells. 
Experimental studies have shown that HPV activates the cell cycle by interfering with the 
function of Rb and p53, two important suppressor genes (157). 
Even though HPV has been firmly established as a causative factor for cancer of the cervix, the 
evidence does not implicate HPV as the only factor. A high percentage of young women are 
infected with one or more HPV types during their reproductive years, and only a few develop 
cancer. Other carcinogens, the immune status of the individual, and hormonal and other factors 
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influence whether the HPV infection will regress or persist eventually progressing to cancer 
(159). 
 
1.2.1. Cervical intraepithelial neoplasia 
 
The classification of cervical precancerous lesions has evolved over the time and the terms from 
the different classification systems are currently used interchangeably (table 1) (157). Hence a 
brief review of the terminology is warranted. The oldest classification system classified lesions 
as having mild dysplasia on one end and severe dysplasia/carcinoma in situ on the other. This 
was followed by cervical intraepithelial neoplasia (CIN) classification, with mild dysplasia 
termed CIN I, moderate dysplasia termed CIN II, and severe dysplasia termed CIN III. Because 
the decision with regard to patient management is two-tiered (observation versus surgical 
treatment), the three-tier classification system has been recently simplified to a two-tier, with 
CIN I renamed as low-grade squamous intraepithelial lesion (LSIL) and CIN II and CIN III 
combined into one category referred to as high-grade squamous intraepithelial lesion (HSIL) 
(157). 
 
Table 1. Classification systems for premalignant squamous cevical lesions. Adopted 
from Hendrick Ellenson L et Pirog EC (157) 
Dysplasia/Carcinomain Situ Cervical Intaepithelial 
Neoplasia (CIN) 
Squamous Intraepithelail 
Lesion (SIL)* 
Mild dysplasia CIN I Low-grade SIL (LSIL) 
Moderate dysplasia CIN II High-grade SIL (HSIL) 
Severe dysplasia CIN III High-grade SIL (HSIL) 
Carcinoma in situ CIN III High-grade SIL (HSIL) 
*current classification 
LSILs are associated with productive HPV infection, but show no significant disruption or 
alteration of the host cell cycle. Most LSILs regress spontaneously, with only a small percentage 
progressing to HSIL. LSIL does not progress directly to invasive carcinoma. For these reasons 
LSIL is not treated like a premalignant lesion. In HSIL, there is a progressive deregulation of cell 
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cycle by HPV, which results in increased cellular proliferation, decreased or arrested epithelail 
maturation, and a lower rate of viral replication, as compared with LSIL. HSILs are one tenth as 
common as LSILs (157). 
Morphology. The diagnosis of SIL is based on identification of nuclear atypia characterized by 
nuclear enlargement, hyperchromasia (dark staining) presence of coarse chromatine granules, 
and variation of nuclear sizes and shapes. The nuclear changes may be accompanied by 
cytoplasmic halos indicating disruption of the cytoskeleton before release of the virus into the 
environment. Nuclear alteration and perinuclear halo are termed koilocyticatypia. The grading of 
SIL into low and high grade is based on expansion of the immature cell layer from its normal, 
basal location. If the atypical, immature squamous cells are confined to the lower one third of the 
epithelium, the lesion is graded as LSIL; if they expand to two thirds of the epithelial thickness, 
it is graded as HSIL (157). 
More than 80% of LSILs and 100% of HSILs are associated with high oncogenic risk HPVs. 
HPV 16 is the single most common HPV type detected in both categories of lesions (164). 
Although the majority of HSILs develop from LSILs, approximately 20% of cases of HSIL 
develop “de noveo”, without the pre-existing LSIL (165). 
These findings underscore that the risk of developing precancer and cancer is conferred only in 
part by HPV type, and depends also on immune status and environmental factors. Progression 
from squamous intraepithelial lesion (SIL) to invasive carcinoma, when it occurs, may take place 
in a few months to more than a decade (157). 
 
1.2.2. Cervical Cancer 
 
Cervical cancer is the fourth common type of cancer in woman (166). Squamous cell carcinoma 
(SCC) is the most common histologic subtype of cervical cancer, accounting for approximately 
80% of cases. As outlined above, HSIL is an immediate precursor of SCC. The second most 
common type is cervical adenocarcinoma, which constitutes about 15% of cervical cancer cases 
and develops from a precursor lesion called adenocarcinoma in situ. Adenosquamous and 
neuroendocrine carcinomas are rare cervical tumours that account for the remaining 5% of cases. 
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All of the above tumour types are caused by high oncogenic risk HPVs. The peak of incidence of 
invasive cervical carcinoma is 45 year (157). 
Infection by “highly oncogenic” Human Papillomavirus (HPV) is essential for cervical cancer 
development (167). However, although infection by highly oncogenic HPVs is essential for the 
development of cervical cancer, it alone is not sufficient; therefore, other cancer related risk 
factors such as host genetic factors (i.e., gene and chromosome alterations, changes in levels of 
tumour suppressors and activators) are necessary for this disease to develop (168,169). 
Therefore, there is an urgent need to clarify the molecular mechanisms behind cervical cancer. 
Despite the presently available screening tests, nearly 266,000 deaths and 528,000 new cases of 
cervical cancer occur annually around the world; this finding shows the inadequacy of existing 
screens and the need for effective screening strategies (166). Consequently, the elucidation of 
potential biomarkers for the screening, diagnosis, and monitoring of cervical cancer constitutes a 
significant research area for further research. 
The computational integration of biomolecular networks with data from different omic levels 
represents the core of research in the field of systems biology. This interdisciplinary field 
provides valuable information on genome reprogramming under disease conditions and relevant 
biological entities that might be considered potential diagnostic or therapeutic targets (170). In 
this context, considering the unclear etiology of cervical cancer and the inaccuracy of present 
screening methods, systems-level approaches are needed. 
 
 
Morphology. SCC may manifest as either fungating (exophytic) or infiltrative cancers. On 
histologic examination, SCC are composed of nests and tongues of malignant squamous 
epithelium, either keratinizing or nonkeratinizing (157). 
In cases in which the medical diagnosis of cervical cancer is made at a late stage, the mean 
survival is less than one year (168); therefore, it is crucial to develop effective screening tests 
that are capable of providing early detection and prevention. Pap smear is widely used in 
screening; however, there are limitations regarding its specificity and sensitivity (171). The 
search for new methods that can improve the early detection of cervical cancer could reduce the 
morbidity and mortality of patients. The researchers have demonstrated that cancer is a 
multistage process that results from an accumulation of multiple genetic changes (172,173).  The 
  23 
 
acquisition of genomic instability, a condition that predisposes a cell to accumulate stable 
genome mutations, represents an early step in the process of carcinogenesis (15). Each genetic 
alteration or mutation, whether an initiating or a progression-associated event, can be mediated 
through a gross chromosomal change and therefore has the potential to be cytogenetically 
detectable (174). Therefore, it is imperative to use some biomarkers of DNA damage due to 
genomic instability to predict cancer risk as well as to identify high-risk individuals (175). 
 
 
1.3. Micronuclei in peripheral blood lymphocytes 
 
Assuming that the mechanisms for the induction of chromosomal damage are similar in different 
tissues, the extent of chromosomal damage evaluated in lymphocytes and other surrogate tissues 
is likely to reflect the level of damage in cancer-prone tissues and, in turn, cancer risk (176). 
It is evident that multiple molecular mechanisms can lead to the formation of MN, NPB and 
NBUD (Table 2). These biomarkers are observed the best in cytokinesis-block micronucleus 
cytome (CBMN cyt) assay, which allows these events to accumulate in cells that have completed 
DNA synthesis and mitosis, which are essential for their expression (177). 
Scientists have demonstrated that the level of genetic damage in peripheral blood lymphocytes 
(PBL) reflects the amount of damage in the precursor cells, which subsequently leads to the 
carcinogenic process in target tissues (176,178,179). The use of biomarkers associated with this 
event may provide effective tools for the early detection of the changes related to cancer. 
One of the cytogenetic biomarkers for predicting cancer risk in humans is the micronucleus 
(MN) in peripheral blood lymphocytes (180,181). 
MN and other nuclear anomalies such as nucleoplasmic bridges (NPBs) and nuclear buds 
(NBUDs) are biomarker of genotoxic events and manifestations of chromosomal instability that 
are often seen in cancer (177). 
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Table 2. Molecular events associated with expression of micronucleus, nucleoplasmic bridge 
and nuclear bud.  Adopted from Fenech M (177) 
CBMNcyt assay 
Biomarker 
Molecular events associated with biomarker 
MICRONUCLEUS Lagging acentric chromosome or chromatid         
fragment at anaphase 
Misrepair of DNA breaks 
Unrepaired DNA breaks 
Lagging whole chromosomes at anaphase 
Hypomethylation of repeat sequences in   
centromeric and pericentromeric DNA 
Defects in kinetochore proteins or assembly 
Dysfunctional spindle 
Defective anaphase checkpoint genes 
Unresolved replication stress intermediates 
NUCLEOPLASMIC BRIDGE Dicentric or multicentric chromosomes with 
centromeres pulled to opposite poles of the 
cell at anaphase 
Misrepair of DNA breaks 
Telomere end fusions due to excessively short 
telomeres 
dysfunctional telomeres or lack of telomeres 
Defective separation of sister chromatids at 
anaphase due to failure of decatenation 
Unresolved replication stress intermediates 
NUCLEAR BUD Active process of elimination of nuclear 
material from nucleus 
Elimination of amplified DNA possibly 
generated via BFB cycles 
Elimination of DNA repair DNA-protein 
complexes 
Elimination of excess chromosomes—may 
occur in polyploid cells to facilitate 
aneuploidy rescue 
Shrinkage of the remnants of a broken NPB   
between two nuclei can result in a temporary 
NBUD on one or both nuclei 
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1.4. Micronucleus  in buccal exfoliated cells 
 
The Buccal Micronucleus Assay is a minimally invasive method for studying DNA damage, 
chromosomal instability. This method is increasingly used in molecular epidemiological studies 
for investigating the impact of genotoxin exposure and genotype on DNA damage, chromosome 
malsegregation. The biomarkers measured in this assay have been associated with increased risk 
of cancer diseases (182). 
As well as the MN test in PBL, the MN test in exfoliated buccal cells is an attractive candidate 
for the genotoxicbio monitoring of human populations and individuals, especially because of its 
non-invasive application nature (183). 
In 1997, The International Human Micronucleus (HUMN) Project was founded to coordinate 
worldwide research efforts aimed at using MN assays to study DNA damage in human 
populations (184).  
Among the large number of laboratories engaged in these projects, it is also the Genetic 
Laboratory of the Department of Biology of the Faculty of Natural Sciences, University of 
Pristina, Kosovo, which has made a number of researches using MN assay in different types of 
human and animals cells, contributing to the pooled analyses of the International Collaborative 
Project on Micronucleus Frequency in Human Populations (HUMN) (185). 
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2. HYPOTHESIS 
 
The effect of pre-cancer and cancer lesions of cervix on induction of the genetic instability can 
be determined using the (MN) assays in exfoliated buccal cells and peripheral blood 
lymphocytes. 
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3. AIMS OF THE STUDY 
 
 
3.1.  GENERAL AIM 
The aim of this research is to evaluate the effect of different stages of cervical precancerous 
lesions and cervical cancer in the induction of genetic instability using frequency of micronuclei 
in the peripheral blood lymphocytes and buccal exfoliated epithelial cells 
 
3.2. SPECIFIC AIMS 
 
1. To determine the frequency of MN in buccal cells and peripheral blood lymphocytes in 
healthy individuals, patients with LSIL, patients with HSIL and patients with invasive squamous 
cell carcinoma.  
2. To determine the correlation of MN frequency in buccal cells and peripheral blood 
lymphocytes of healthy individuals, patients with LSIL, patients with HSIL and patients with 
invasive squamous cell carcinoma. 
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4. MATERIALS AND METHODS 
 
 
4.1. Materials /Subjects 
 
This doctoral thesis was conducted in the Faculty of Natural Sciences - Department of Biology, 
University of Pristina, and Institute of Pathology and Gynecology and Obstetrics Clinic of 
University Clinical Center of Kosovo, Medical Faculty, University of Pristina, Kosovo. 
The study included 100 subjects aged between 26 and 68 years, of which 80 female patients were 
previously histologically diagnosed with: 
 low-grade squamous intraepithelial lesions (LSIL) (n= 20) 
 high-grade squamous intraepithelial lesions (HSIL) (n= 40) 
 invasive squamous cell carcinoma (SCC) of cervix (n=20)  
and the control group included healthy women, negative for intraepithelial squamous lesions 
(n=20) 
 
This study was approved by the ethical committee of the University Clinical Centre of Kosovo 
(No. 563, date: 07 February 2012). All subjects were informed about the study and gave a 
written consent for the participation. 
Exclusion criteria: None of the subjects had any chemotherapy or radiotherapy, history of cardiac 
disease, infective disease and did not consume alcohol or cigarettes. 
The chosen sample was very homogenous. They were collected in a period of time for about 
three years. 
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4.2. Methods 
 
4.2.1. Cytokinesis-block micronucleus cytome (CBMN cyt) assay 
 
The CBMN cyt assay was prepared and scored according to the method of Fenech (25) and  
Fenech and Morley (186). 
Venous blood samples were obtained from 20 patients histologically diagnosed with LSIL, 40 
patients with HSIL, 20 patients with SCC and 20 healthy women. 
PROCEDURE 
Culture of lymphocytes (TIMING 72h) 
Peripheral blood samples (5 ml) were collected by heparinized sterile injector. Whole blood (0.5 
ml) was added to 5 ml of complete medium for the cultivation of cells PBMax Karyotyping 
(Invitrogen, Carlsbad, CA). All cultures were set up in duplicates and incubated at 37 °C up to 
72 hours. 
 
Addition of Cytochalasin B to culture (TIMING 10 min) 
Binucleated cells were accumulated by adding cytochalasin B (Cyt B) (Sigma-Aldrich, St. Louis, 
MO) to a final concentration of 3μg/ml at the 44th h following the initiation of the culture sample.  
 
Harvesting of cells using centrifugation (TIMING approximately 30 min) 
At the end of 72h, samples were centrifuged and re-suspended in 0.075 M KCl at 4°C for 3 min 
for hypotonic treatment. Cells were fixed with methanol–acetic acid (3:1) three times. 
 
Drying, fixing and staining of cells and slide preparation (TIMING approximately 30 min) 
The centrifuged cells were resuspended in a small volume of fixative and spread onto the 
specially prepared, cold and lamp-dried slides. The slides were stained with 5% Giemsa solution 
for 10 minutes.  
 
Slide Scoring (TIMING 40 min per slide) 
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The cells were analysed under light-microscopy (x400), by scoring 1000 binucleated 
lymphocytes (500 per each culture) per subject, in which the number of MNi, NPBs and NBUDs 
in PBL were scored by two independent scorers. 
 
Scoring criteria in PBL 
 
Criteria for selecting BN cells suitable for scoring MNi, NPBs and NBUDs 
The cytokinesis-blocked BN cells that may be scored for MN, NPB and NBUD frequency should 
have the following characteristics:  
 The cells should be binucleated. 
 The two nuclei in a binucleated cell should have intact nuclear membranes and be 
situated within the same cytoplasmic boundary. 
 The two nuclei in a binucleated cell should be approximately equal in size, staining 
pattern and staining intensity.  
 The two nuclei within a BN cell may be attached by a nucleoplasmic bridge, which is no 
wider than 1/4th of the nuclear diameter. 
 The two main nuclei in a BN cell may touch but ideally should not overlap each other. A 
cell with two overlapping nuclei can be scored only if the nuclear boundaries of each 
nucleus are distinguishable.  
 The cytoplasmic boundary or membrane of a binucleated cell should be intact and clearly 
distinguishable from the cytoplasmic boundary of adjacent cells.  
Criteria for scoring micronuclei in PBL 
Micronuclei are morphologically identical to, but smaller, than nuclei. They also have the 
following characteristics:  
 The diameter of MNi in human lymphocytes usually varies between 1/16th and 1/3rd of 
the mean diameter of the main nuclei, which corresponds to 1/256th and 1/9th of the area 
of one of the main nuclei in a BN cell, respectively.  
 MNi are non-refractile and they can therefore be readily distinguished from artefact such 
as staining particles. 
 MNi are not linked or connected to the main nuclei. 
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 MNi may touch but not overlap the main nuclei and the micronuclear boundary should be 
distinguishable from the nuclear boundary. 
 MNi usually have the same staining intensity as the main nuclei but occasionally staining 
may be more intense.  
 
Criteria for scoring nucleoplasmic bridges in PBL 
 An NPB is a continuous DNA-containing structure linking the nuclei in a binucleated 
cell. NPBs originate from dicentric chromosomes (resulting from misrepaired DNA 
breaks or telomere end fusions) in which the centromeres are pulled to opposite poles 
during anaphase. They have the following characteristics:  
 The width of an NPB may vary considerably but usually does not exceed 1/4th of the 
diameter of the nuclei within the cell. 
 NPBs should also have the same staining characteristics as the main nuclei. 
 On rare occasions, more than one NPB may be observed within one binucleated cell.  
 A binucleated cell with an NPB may contain one or more MNi.  
 BN cells with one or more NPBs and no MNi may also be observed.  
It may be more difficult to score NPBs in BN cells with touching nuclei, and it is therefore 
reasonable to specify whether NPBs were scored in all BN cells regardless of proximity of nuclei 
within a BN cell or whether they were scored separately in those BN cells in which nuclei were 
clearly separated and those BN cells with touching nuclei. There is not enough evidence yet to 
recommend scoring NPB only in BN cells in which nuclei do not touch. 
 
Criteria for scoring nuclear buds in PBL 
An NBUD represents the mechanism by which a nucleus eliminates amplified DNA and DNA 
repair complexes. NBUDs have the following characteristics: 
 NBUDs are similar to MNi in appearance with the exception that they are connected with 
the nucleus via a bridge that can be slightly narrower than the diameter of the bud or by a 
much thinner bridge depending on the stage of the extrusion process.  
 NBUDs usually have the same staining intensity as MNi.  
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 Occasionally, NBUDs may appear to be located within a vacuole adjacent to the nucleus. 
 If it is difficult to determine whether the observed nuclear anomaly is an MN touching the 
nucleus or a nuclear bud, it is acceptable to classify it as the latter. 
 
 
 
4.2.2. Buccal Micronucleus Assay 
 
The MN in BEC was prepared and scored according to the method of Tolbert et al. (187) and 
Thomas et al. (182). 
 
 
PROCEDURE: 
 
Buccal cell collection (TIMING 10 min) 
Buccal epithelial cells were collected simultaneously with the peripheral blood samples from 
patients, as well as, controls. Prior to buccal cell collection the mouth was rinsed thoroughly with 
water to remove any unwanted debris. Small headed toothbrushes were used to collect buccal 
cells by rotating the brush 20 times in a circular motion against the inside of the cheek, starting 
from a central point and gradually increasing in circumference to produce an outward spiral 
effect. 
 
Buccal cell harvesting and slide preparation (TIMING 2 h) 
The heads of the brushes were individually placed into separate 30 ml yellow top containers, 
containing buccal cell buffer (0.01 M Tris-HCL; Sigma T-3253), 0.1 M EDTA tetra sodium salt 
heads (Sigma E5391), 0.02 Sodium chloride (Sigma S5886) at pH 7.0 and agitated to dislodge 
cells. Cells were transferred into separate TV-10 centrifuge tubes and spun for 10 min at 1500 
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rpm (Sigma 2000). Slides containing two spots of cells were air dried for 10 min and then fixed 
in a mixture of ethanol and acetic acid (3:1) for 10 min.  
 
 
Buccal cell staining for microscopy (TIMING 30 min) 
After that, slides were air dried for another 10 minutes prior Giemsa staining. 
 
 
Scoring (TIMING 60-80 min per slide) 
The micro nucleated cells were analysed under light-microscopy (x 400), by scoring 2000 buccal 
exfoliated cells (per subject), by two independent scorers.  
 
 
Criteria for identifying and scoring the MN in the Buccal Micronucleus Assay 
Cells with micronuclei are characterized by the presence of both a main nucleus and one or more 
smaller nuclear structures called micronuclei (MNi). The micronuclei are round or oval in shape 
and their diameter should range between 1/3 and 1/16 of the main nucleus. MNi have the same 
staining intensity and texture as the main nucleus. The nuclei in micronucleated cells have the 
morphology of nuclei in normal cells. The MNi must be located within the cytoplasm of the 
cells. MNi are scored only in differentiated cells with uniformly stained nuclei. Cells, which are 
pyknotic (i.e., shrunken nuclei), and have condensed chromatin or karyorrhectic nuclei (see 
below), are not scored for MNi. 
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4.3. Statistical analysis 
 
One-way ANOVA was performed to assess the significance of differences in study variables 
across study groups (control group, LSIL group, HSIL group and SCC of cervix group) with 
Tukey’s HSD post-hoc test for multiple comparisons. Independent samples T-test was performed 
to assess the significance of differences in study variables in two groups. Pearson’s correlation 
test was performed to examine the relationship between study variables in study groups. The 
results are expressed as mean± standard deviation (SD). All statistical analyses were done with 
SPSS, version 20.0 (SPSS Inc., Chicago, IL). A value of p<0.05 was considered statistically 
significant.  
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5. RESULTS 
 
 
5.1. Analysis of results in the overall number of patients  
 
- Analysis of the MN frequency in BEC, MN in PBL as well as NPB and NBUD in 
PBL between patients group and control group 
 
Independent samples T-test showed a highly statistically significant difference between the 
patients and the control group in all four study variables (Table 3, Figure 4). 
Table 3, shows statistically significant difference in MN in BEC and MN in PBL between patient 
group (n=80) and control group (n=20) (p< 0.001) as well as for NPB and NBUD in PBL 
between patients and control group (p<0.001). 
 
Pearson’s correlation revealed a statistically significant positive correlation between the variables 
in patients group (table 4), especially, a strong significant positive correlation was found between 
MN in PBL and MN in BEC (r=0.502 and p<0.0001) (Figure 5); between MN in PBL and NPB 
in PBL(r=0.559 and p< 0.0001) (Figure 6);  between MN in PBL and NBUD in PBL (r=0.415 
and p< 0.0001) (Figure 7) and between NPB in PBL and NBUD in PBL(r=513 and p<0.0001) 
(Figure 8). Moderate significant positive correlation was found between MN in BEC and NPB in 
PBL (r=374 and p<0.001) (Figure 9) as well as between MN in BEC and NBUD in PBL (r=364 
and p<0.001) (Figure 10).  
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Table 3. The frequency of MN in BEC and PBL, frequency of NPB and NBUD in PBL, 
between control group (n=20) and overall number of patients (n=80) 
 MN in BEC MN in PBL NPB in PBL NBUD in PBL 
Mean±SD Min-
Max 
Mean±SD Min-
Max 
Mean±SD Min-
Max 
Mean±SD Min-
Max 
Control 
group 
(n=20) 
3.15±1.22 2-6 3.00±1.83 1-9 0.70±1.45 0-6 0.20±0.52 0-2 
Patients  
(n=80) 
6.32±0.73 0-20 7.66±4.79 1-22 1.72±2.43 0-15 1.07±1.37 0-7 
P-value A:B, p<0.001* 
 
A:B, p<0.001* 
 
A:B, p= 0.001* 
 
 
A:B, p<0.001* 
 
 
*Statistically significant value is considered when p<0.05; A-Control group; B- Patients. MN -
micronucleus; BEC – buccal exfoliated cell; PBL-peripheral blood lymphocytes; NPB- 
nucleoplasmic bridge; NBUD- nuclear bud 
 
 
 
 
 
 
 
 
 
 
 
  37 
 
 
 
Figure 4. Frequencies of MN in BEC, MN, NPB and NBUD in PBL of control group (n=20) and 
overall number of patients (n=80). MN - micronucleus; BEC – buccal exfoliated cell; PBL-
peripheral blood lymphocytes; NPB- nucleoplasmic bridge; NBUD- nuclear bud 
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Table. 4. Correlation between variables (MN in BEC, MN in PBL, NPB in PBL and NBUD in 
PBL) in two main groups (control and overall number of patients) 
 
  MN in 
PBL:MN 
in BEC 
MN in 
PBL:NPB 
in PBL 
MN in 
PBL:NBUD 
in PBL 
MN in  
BEC 
:NPB in 
PBL 
MN in 
BEC: 
NBUD in 
PBL 
NPB in 
PBL: 
NBUD in 
PBL 
Control 
group(n=
20) 
r 0.164 0.217 0.658 0.322 0.443 0.083 
p 0.490 0.358 0.002* 0.167 0.050* 0.728 
Patients 
group 
(n=80) 
r 0.502 0.559 0.415 0.374 0.364 0.513 
p 0.000*** 0.000*** 0.000*** 0.001** 0.001** 0.000*** 
*Statisticlly siginificant positive correlation is considered when p<0.05 
 **Moderate statistically significant positive correlation is considered when p<0.001 
*** Strong statistically significant positive correlation is considered when p<0.00001 
 
MN - micronucleus; BEC – buccal exfoliated cell; PBL-peripheral blood lymphocytes; NPB- 
nucleoplasmic bridge; NBUD- nuclear bud 
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+   
Figure 5. Results of Pearson’s correlation between MN in PBL and MN in BEC. MN - 
micronucleus; PBL-peripheral blood lymphocyte; BEC – buccal exfoliated cell 
 
 
Figure 6. Results of Pearson’s correlation between MN in PBL and NPB in PBL. MN - 
micronucleus; PBL-peripheral blood lymphocytes; NPB- nucleoplasmic bridge 
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Figure 7. Result of Pearson’s correlation between MN in PBL and NBUD in PBL.MN - 
micronucleus; PBL-peripheral blood lymphocytes; NBUD- nuclear bud 
 
 
Figure 8. Result of Pearson’s correlation between NPB in PBL and NBUD in PBL. NPB- 
nucleoplasmic bridge; PBL-peripheral blood lymphocytes; NBUD- nuclear bud 
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Figure 9. Result of Pearson’s correlation between MN in BEC and NPB in PBL. MN - 
micronucleus; BEC – buccal exfoliated cell; NPB- nucleoplasmic bridge; PBL-peripheral blood 
lymphocytes 
 
Figure 10. Result of Pearson’s correlation between MN in BEC and NBUD in PBL. MN -
micronucleus; BEC – buccal exfoliated cell; PBL-peripheral blood lymphocytes; NBUD- nuclear 
bud 
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5.2. Analysis of results in each group of patients  
 
- Analysis of MN in BEC, MN in PBL as well as NPB in PBL and NBUD in PBL 
between LSIL, HSIL, SCC group and control group 
 
One-way ANOVA showed statistically significant differences (p<0.001) between groups in all 
four study variables (Figure 11). 
 
Figure 11. Results of one-way ANOVA considering frequencies of MN in BEC, MN in PBL, 
NPB in PBL and NBUD in PBL across studied groups.MN - micronucleus; BEC – buccal 
exfoliated cell; PBL-peripheral blood lymphocytes; NPB- nucleoplasmic bridge; NBUD- nuclear 
bud 
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5.2.1.   Analysis of MN in PBL  
 
Multiple comparisons with Tukey’s post-hoc test were run to show which groups differed the 
most from each other. 
Tukey’s post-hoc test showed there was a statistically significant difference in MN in PBL 
between SCC group and control, LSIL and HSIL group (p< 0.00001, p<001 and p<0.01, 
respectively) (Table 5), as well as between LSIL group and HSIL group (p=0.01), and HSIL 
group and control group (p<0.001), but no statistically significant difference between LSIL 
group and control group (p=0.824) (Table 5, Figure 12, 13 ).  
 
 
 
Table 5. The frequency of MN in PBL between LSIL, HSIL, SCC and control group 
Study groups 
 
MN in PBL 
Mean±SD Min-Max 
Control group (n=20) 3.00±1.83a 1-9 
LSIL group (n=20) 3.90±2.77b 1-11 
HSIL group (n=40) 7.50±3.23c 2-15 
SCC group of cervix (n=20) 11.75±4.74d 3-22 
p-value 0.000000 
* Statistically significant value is considered when p<0.05;  a-control group; b-LSIL; c-HSIL; 
d-SCC 
d:a, p<0.00001; d:b, p<0.001; d:c, p<0.01; c:a, p<0.001; c:b,p<0.01; b:a,p=824 
 
MN - micronucleus; PBL-peripheral blood lymphocytes; LSIL - low-grade squamous 
intraepithelial lesions; HSIL - high-grade squamous intraepithelial lesions; SCC - invasive 
squamous cell carcinoma  
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Figure 12. Binuclear lymphocytes (BN) in CBMN cyt assay. The arrow show normal cell 
cytokinesis-blocked. Giemsa. (x 400). 
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Figure 13. Binuclear lymphocytes (BN) in CBMN cyt assay. BN containing MN (black arrow). 
Giemsa. (x 400). MN - micronucleus. 
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5.2.2. Analysis of NPB in PBL 
 
 
A statistically significant difference was shown also in NPB in PBL between SCC group of 
cervix and other study groups (p=0.01, p<0.01 and p=0.006, respectively), but not between LSIL 
group and HSIL group (p=0.377) and between LSIL and HSIL groups and control group 
(p=0.996 and p=0.534, respectively) (Table 6, Figure 14). 
 
Table 6. The frequency of NPB in PBL between LSIL, HSIL, SCC and control group 
Study groups NPB in PBL 
Mean±SD Min-Max 
Control group (n=20) 0.70±1.45a 0-6 
LSIL group (n=20) 0.55±0.76b 0-2 
HSIL group (n=40) 1.47±2.09c 0-11 
SCC group of cervix (n=20) 3.40±3.25d 0-15 
p-value 0.000101 
* Statistically significant value is considered when p<0.05;  a-control group; b-LSIL; c-HSIL; 
d-SCC  
d:a, p=0.01 ;  d:b, p<0.01;  d:c, p=0.0061;   c:a, p=0.534;  c:b, p=0.377;  b:a,p=0.996 
 
NPB - nucleoplasmic bridge; PBL-peripheral blood lymphocytes; LSIL - low-grade squamous 
intraepithelial lesions; HSIL - high-grade squamous intraepithelial lesions; SCC - invasive 
squamous cell carcinoma  
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Figure 14. Binuclear lymphocytes (BN) in CBMN cyt assay. BN containing NPB (black arrow). 
Giemsa. (x 400). NPB- nucleoplasmic bridge 
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5.2.3. Analysis of NBUD in PBL 
 
As for NBUD in PBL, a statistically significant difference was shown between SCC group of 
cervix and control group and LSIL group (p<0.001 and p=0.002, respectively), as well as 
between HSIL group and control group (p=0.033), but no statistically significant difference 
between SCC group of cervix and HSIL group (p=0.195), LSIL group and HSIL group 
(p=0.103) as well as between LSIL and control group (p=0.978) (Table 7, Figure 15 ). 
 
Table 7. The frequency of NBUD in PBL between LSIL, HSIL, SCC and control group 
Study groups NBUD in PBL 
Mean±SD Min-Max 
Control group (n=20) 0.20±0.52a 0-2 
LSIL group (n=20) 0.35±0.67b 0-2 
HSIL group (n=40) 1.10±1.41c 0-7 
SCC group of cervix (n=20) 1.75±1.52d 0-5 
p-value 0.000137 
* Statistically significant value is considered when p<0.05;  a - control group; b - LSIL; c - 
HSIL; d -SCC 
d:a, p<0.001; d:b, p=0.002; d:c, p=0.195;  c:a, p=0.033;  c:b, p=0.103; b:a, p=0.978 
NBUD – nuclear bud; PBL - peripheral blood lymphocytes; LSIL - low-grade squamous 
intraepithelial lesions; HSIL - high-grade squamous intraepithelial lesions; SCC - invasive 
squamous cell carcinoma  
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Figure 15.  Binuclear lymphocytes (BN) in CBMN cyt assay. BN containing NBUD (black 
arrow). Giemsa. (x 400). NBUD – nuclear bud 
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5.2.4. Analysis of MN in BEC 
 
Multiple comparisons with Tukey’s post-hoc test show which groups differed the most from 
each other and showed that there was a statistically significant difference in MN in BEC between 
SCC group of cervix and all other study groups (p<0.001), reached a borderline significance 
between LSIL groups and HSIL group (p=0.50), and no statistically significant difference 
between LSIL and HSIL groups with the control group (p=0.996 and p=0.094, respectively) 
(Table 8, Figure 16). 
 
 
Table 8. The frequency of MN in BEC between LSIL, HSIL, SCC and control group  
Study groups MN in BEC  
Mean±SD Min-Max 
Control group (n=20) 3.15±1.22a 2-6 
LSIL group (n=20) 2.95±1.57b 1-6 
HSIL group (n=40) 4.92±3.06c 0-14 
SCC group of cervix (n=20) 12.50±3.90d 6-20 
p-value 0.000000 
* Statistically significant value is considered when p<0.05;  a - control group; b - LSIL; c - 
HSIL; d -SCC 
d:a, p<0.001 ;  d:b, p<0.001;  d:c, p=0.001;   c:a, p=0.094;  c:b, p=0.50;  b:a,p=0.996 
MN - micronucleus; BEC–buccal exfoliated cell; LSIL - low-grade squamous intraepithelial 
lesions; HSIL - high-grade squamous intraepithelial lesions; SCC - invasive squamous cell 
carcinoma  
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Figure 16. MN test in BEC. Buccal exfoliated cell with MN (black arrow). Giemsa. (x 400). MN 
– micronucleus; BEC - buccal exfoliated cell 
 
 
Independent samples T-test showed statistically significant difference between HSIL groups 
(CIN 2 and CIN 3) in MN in PBL (p=0.04) but no significant difference between groups was 
shown in other study variables (MN in BEC, NPB in PBL and NBUD in PBL). 
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- Correlation between variables (MN in BEC, PBL; NPB and NBUD in PBL) in LSIL, 
HSIL, SCC and control group 
 
Pearson’s correlation showed a strong positive correlation between MN in PBL and NPB in PBL 
in SCC group (r=0.594, p=0.006); between MN in PBL and NBUD in PBL in control group 
(r=0.658, p<0.02). Moderate positive significant correlation was shown between NPB in PBL 
and NBUD in PBL (r=0.473, p<0.035) in LSIL group; between MN in PBL and MN in BEC 
(r=0.378, p<0.016) in HSIL group. The other correlation between variables didn’t show any 
significant correlation between them (Table 9, Figure 17-22). 
Table 9. Pearson’s correlation coefficients and significance for all variables in all study groups 
  MN in 
PBL:MN 
in BEC 
MN in 
PBL:NPB 
in  PBL 
MN in  
PBL:NBUD 
in  PBL 
MN in 
BEC 
:NPB in 
PBL 
MN in 
BEC: 
NBUD in 
PBL 
NPB in 
PBL: 
NBUD in 
PBL 
Control 
group(n=20) 
r 0.164 0.217 0.658 0.322 0.443 0.083 
p 0.490 0.358 0.002 0.167 0.050 0.728 
LSIL group 
(n=20) 
r 0.156 0.328 0.473 -0.196 0.317 0.119 
p 0.512 0.158 0.035 0.407 0.173 0.618 
HSIL group 
(n=40) 
r 0.378 0.265 0.214 0.198 0.127 0.793 
p 0.016 0.099 0.185 0.220 0.436 0.0000 
SCC group 
(n=20) 
r -0.235 0.594 0.283 -0.021 0.253 0.043 
p 0.319 0.006 0.226 0.931 0.281 0.858 
Differences were considered statistically significant at p<0.05.  MN - micronucleus; BEC – 
buccal exfoliated cell; PBL-peripheral blood lymphocytes; NPB- nucleoplasmic bridge; NBUD- 
nuclear; LSIL - low-grade squamous intraepithelial lesions; HSIL - high-grade squamous 
intraepithelial lesions; SCC - invasive squamous cell carcinoma 
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Figure 17. Relationship between frequency of MN in BEC and MN in PBL, within different 
groups (Pearson’s Correlation). MN - micronucleus; BEC – buccal exfoliated cell; PBL-
peripheral blood lymphocytes 
 
Figure 18. Relationship between frequency of MN in PBL and NPB in PBL, within different 
groups (Pearson’s Correlation). MN - micronucleus; PBL-peripheral blood lymphocytes; NPB- 
nucleoplasmic bridge 
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Figure 19. Relationship between frequency of MN in PBL and NBUD in PBL, within different 
groups (Pearson’s Correlation). MN - micronucleus; PBL-peripheral blood lymphocytes; NBUD- 
nuclear 
 
 
Figure 20. Relationship between frequency of MN in BEC and NPB in PBL, within different 
groups (Pearson’s Correlation). MN - micronucleus; BEC – buccal exfoliated cell; NPB- 
nucleoplasmic bridge; PBL-peripheral blood lymphocytes 
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Figure 21. Relationship between frequency of MN in BEC and NBUD in PBL, within different 
groups (Pearson’s Correlation). MN- micronucleus; BEC- buccal exfoliated cell; NBUD – 
nuclear bud; PBL - peripheral blood lymphocytes 
 
 
Figure 22. Relationship between frequency of NPB in PBL and NBUD in PBL, within different 
groups (Pearson’s Correlation). NPB - nucleoplasmic bridge; NBUD – nuclear bud; PBL - 
peripheral blood lymphocytes 
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6. DISCUSSION 
 
 
The search of cytogenetic biomarkers for the identification of groups and/or individuals at high 
risk of cancer is an important task in public health (188). Biological markers are important aspect 
of the diagnosis, prognosis and risk assessment of a disease (189).  
The hypothesis of an association between MN frequency and cancer development is supported 
by a number of observations, the most substantial of which include the high MN frequency in 
untreated cancer patients, subjects affected by cancer-prone congenital diseases and in patients 
with different types of cancer (22,178,190,191,192). 
 
In prospective studies evaluating large cohorts of disease-free subjects, an increase in 
micronuclei (MN) frequency in peripheral blood lymphocytes was associated with an increased 
cancer risk at the population level, providing suggestive evidence that this biomarker may be 
predictive of cancer risk (180,181). Many studies were also published on the application of the 
MN test in peripheral lymphocytes in untreated patients with cancer or pre neoplastic lesions, the 
large majority of them showing a significant increase of MN frequency in patients compared to 
control groups (193),  neurodegenerative diseases (194), cardiovascular diseases and diabetes 
(195). Moreover, an increased MN frequency was detected in subjects affected by cancer-
associated congenital syndromes characterized by a deficiency in DNA damage response 
(196,197). Consequently, there is great interest in the identification and validation of biomarkers 
whose function may reveal insights into critical early events in cervical carcinogenesis and may 
therefore be of utility as potential markers for cancer risk. Considering the fact that no research 
with MN, NPB and NBUD has been done yet in patients with cervical lesions, especially in 
surrogate tissues, our interest was to investigate the genome instability of those patients in 
surrogate tissues. 
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6.1.  The frequency of MN, NPB and NBUD in PBL 
 
The CBMN cyt assay enables measurement of MN as a biomarker of chromosome breakage and 
whole chromosome loss; NPB as a biomarker of dicentric chromosomes that result from 
telomere end fusions or DNA mis-repair; NBUD as a biomarker of gene amplification (25,177). 
Our results indicate that spontaneous genetic damage in lymphocytes of patients having LSIL, 
HSIL and SCC measured through CBMN cyt assay was higher than that of controls, thus 
meaning that genetic instability appeared to exist in lymphocytes of patients having LSIL, HSIL 
and SCC. In the present study, the greatest chromosomal damage was observed in patients 
having SCC. This observation is supported by the conclusions of some other studies 
(198,199,200) on patients having different cervical lesions as well as on patients with different 
cancers (190). Furthermore, the results of this study are in line with existing data that emphasise 
the role of elevated MN frequency in lymphocytes as a biomarker of cancer risk: the first cohort 
studies addressed the risk associated with the frequency of chromosome aberration () in PBL of 
healthy subjects. In 1990, a collaborative initiative carried out in Northern Europe  (201) 
evaluated the risk of cancer incidence in a group of 1548 subjects from Finland, Sweden and 
Norway, free of cancer at the time of cytogenetic analysis. Although the result failed to reach 
statistical significance, the subjects in the highest tertiles of CA frequency experienced a cancer 
incidence almost double compared to the general population [Standardised Incidence Ratio 
(SIR) = 1.82; 95% CI: 0.98–3.01]. These results were consolidated since then by a number of 
new studies, performed in the same population (202,203), in Italy (204,205), in Taiwan (206), in 
the Czech republic (207), in five countries of Central Europe (31), and also by a pooled analysis, 
which assembling a cohort of 22 358 subjects found significant increases of 1.31 (95% CI: 1.07–
1.60) in cancer risk for subjects classified in the medium tertile of CA distribution and 1.41 (95% 
CI: 1.16–1.72) for subjects in the highest tertile (179). 
Since, genetic alterations, including telomere damage, chromosomal aberrations and 
amplification, and epigenetic modifications, are an initial step in the process of carcinogenesis 
(208) and tumour progression (209). Thus, the genomic instability, detected by the MN test can 
  58 
 
be suggested as markers for cancer (210,211), and its monitoring is important in therapeutics, 
especially with the changes in the chromosomes (209,212). Many reports, provided the basic 
evidence to support the causal role of chromosome damage in carcinogenesis (190). 
Evidence that cytogenetic biomarkers are positively correlated with cancer risk has been strongly 
validated in both cohort and nested case-control studies, leading to the conclusion that 
chromosome aberrations are a relevant marker of cancer risk (213), which reflects the outcome 
of both the genotoxic effects of carcinogens and the genetic host susceptibility. Because of this, 
The International Human Micronucleus (HUMN) Project was created in this sense to coordinate 
worldwide research efforts aimed at using CBMN assays to study DNA damage in human 
populations and to establish standardised protocols so that data comparisons can be made more 
reliably across laboratories and countries (184). The launch of the Human MicroNucleus project 
allowed inclusion of archived data on the MN assay performed in the 1990s’ and early 2000s’, 
which provided the bases for recruiting a cohort large enough for epidemiological studies. The 
study assembled subjects whose lymphocytes had been screened for MN frequency between 
1980 and 2002 and who were free of cancer at the time of testing (180). Overall, data on 6718 
individuals studied in 20 cytogenetic laboratories from 10 countries accounting for a total of 
62 980 person-years were studied. To standardise for the inter-laboratory variability subjects 
were classified according to the percentiles of MN distribution within each laboratory as low, 
medium or high frequency. A significant increase of all cancers incidence was found in medium 
and high MN frequency groups accompanied by a decreased cancer-free survival. This 
association was present in all cohorts for all major cancer sites, especially urogenital and 
gastrointestinal cancer. Our data are also in agreement with the above mentioned data. 
The cytokinesis-block micronucleus (CBMN) assay is a relatively fast and easy technique 
extensively used in molecular epidemiology and cytogenetics. The high reliability and low cost 
of the this assay has contributed to its success worldwide and to the adoption for in vitro and in 
vivo studies of genome damage (180). 
Our data are also in agreement with the many papers that have shown an increased baseline 
frequency of MN and other CBMN end points in PBL of cancer patients (22) , confirming the 
presence of a high genetic instability in cancer. The majority of studies reported the presence of 
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increased MN frequencies in individuals with cancer or with preneoplastic lesions. The number 
of studies performed on PBL is quite high. However, all these studies were mostly based on a 
small sample size. The only exceptions are represented by the study of Duffaud et al. (214), 
performed on PBMC – explanation of abbreviation  from 197 controls and 57 head-and-neck 
cancer patients, and the one of El- Zein et al. (191), on lymphocytes from 139 lung cancer cases 
and 130 controls. Since  CBMN cyt assay measures chromosomal DNA damage, cytostasis and 
cytotoxicity events in the cell population (25) it is generally accepted that events of genetic 
damage such as MN and NBUD may represent a reflection of misrepaired DNA breaks, 
dysregulation on telomere length as well as malfunctions in the mitotic machinery and DNA 
amplification (177). An increase in MN frequency may be considered a biomarker of 
chromosome loss and/or breakage, whereas other anomalies such as NBUD are biomarkers of 
gene amplification and/or removal of unresolved DNA repair complexes (22). Several factors 
may have impact in the MN formation and frequency. Lifestyle habits (smoking, alcohol, 
vitamin intake) and host factors (age, gender) are among them, as well as genetic polymorphisms 
and exposure to specific mutagen agents (27). This is in line with previous investigations on the 
impact of smoking on MN levels, in which the MN rates are higher in non-smokers than in 
smokers reviewed by Nersesyan et al. (215). The reduction of MN levels in smokers reported in 
literature is usually present only in light and moderate smokers, whereas heavy smokers have 
higher levels of MN when also occupational exposure is taken into account (107).  
 
Our results are in accordance with results of many studies, showing an increase of MN frequency 
in patients with different types of precancer and cancer (178,190) as well as the association 
between MN, NPB and NBUD in PBL and different lesions (31,216,217). 
 
It was interesting that we have found increased frequency of NPBs in SCC group compare to 
other groups. Since cancer initiation and progression is driven by a series of changes in DNA 
that control gene expression, resulting in uncontrolled cellular proliferation. The mutation theory 
of cancer causation suggests that cancer-associated gene expression arises from random 
replication errors, exposures to carcinogens (e.g., viruses, radiation, cigarette smoke), or faulty 
DNA repair processes. Although HPV infection is necessary for cervical cancer  development, 
progression to cancer occurs in only a small percentage of HPV-infected women, and a number 
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of studies have shown that incident cervicovaginal HPV is self-limited disease generally lasting 
less than a year in duration (218,219,220). Human papillomaviruses (HPVs) play a critical role 
in the etiology of SCC, with several lines of epidemiologic and experimental evidence 
supporting a role for non-viral (co-carcinogens) in controlling the risk for progression to 
neoplasia among HPV-infected individuals (221,222,223), so it has been possible that unknown 
factors included in the etiology of SCC have an impact in increased frequency of  NPB in 
patients with SCC. Recently, the role of co-carcinogens in cervical carcinogenesis have been 
demonstrated by  Haverkos HW et al (224). 
Our results are consistent with some previous reports concerning the increased frequency of 
NPBs in cancer patients (193,225,251). 
 
 
 
 
 
6.2. The frequency of MN in BEC 
 
Since exfoliated buccal cells are a good source of tissue for monitoring genetic damage including 
aneuploidy, as well as clastogenicity in humans, they have increasingly been recognized in many 
countries (226). 
The MN test is fast, simple, minimally invasive, and cheap so, it is well tolerated among patients. 
Also, there is no need to perform cell cultures (185,227). MN are formed during the transition 
metaphase-anaphase of the mitosis and they can appear as complete chromosomes left out 
usually as a consequence of mitotic apparatus damage (aneuploidogenic effect) or chromosome 
fragments without centromere (clastogenic damage); in both cases, these genetic materials were 
unable to be incorporated to daughter cells (228) and they can be differentiated by their size  
(229) or by centromere presence (230). Such events can occur in a spontaneous manner; 
nevertheless, in presence of certain endogenous (231,232), or exogenous factors (185,233), they 
seem to be increased. So, MN presence can be used as a biomarker of mutagenic and genotoxic 
agents influence (234). 
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The presence of MN can be evaluated in many tissues involving dividing cell (234), for example, 
cervix epithelia (198), bladder, esophagus, and bronchial, nasal, and buccal mucosa (185,227). 
Indeed, MN presence has been used as a biomarker of genotoxicity in animals (235) and 
vegetables  (236). 
The oral cavity has been proposed as a mirror that reflects an individual's health, since oral 
mucosa often reflects disease changes; furthermore, it is the first contact with many pollutants 
like tobacco or alcohol and its affection can also be indicative of a systemic condition or side 
effects due to chemotherapy or radiotherapy administration (226, 237). 
Our results regarding of MN in BEC indicated that genetic damage in buccal cells of patients 
with SCC was higher than that of controls, thus meaning that genetic instability appeared to exist 
in buccal cells of those patients. Increased frequency of MN in BEC of patients with SCC 
compare to HSIL, LSIL patients and control group, are indicative of the gradual destabilization 
of the genome. Progressive increase of MN in BEC in patients from LSIL, to HSIL and SCC, are 
indicative of the gradual destabilization of the genome. 
Our data are also in agreement with data providing the importance of evaluating genome 
instability using the micronucleus test in buccal exfoliated cell. Bloching et al. demonstrated that 
buccal MN rates were 2-fold higher in pharyngeal cancer patients compared to healthy subject 
(238). In our study, the frequency of MN in BEC of patients with SCC were 3-fold higher 
compare to control group. Rajeswari et al. suggested that the first-degree relatives of breast 
cancer patients are at an increased cancer risk based on buccal MN frequencies and alkaline 
comet assay as basal DNA damage in lymphocytes (239). 
The squamous epithelium of buccal mucosa has a unique proliferative response which allows 
cellular population to maintain a constant rate of cell divisions; nevertheless, this characteristic 
makes cells prone to DNA damage, a finding that is relevant since it is estimated that 90% of all 
cancers are derived from epithelial cells (226). 
Oral mucosa cells are useful for determining exposure to compounds not only because they are 
the first line of encounter with several environmental factors like tobacco and alcohol, but also 
since several systemic conditions and treatments limit the proliferation rate of epithelial cells 
(237). Other candidate human tissues have been investigated as potential models to reflect 
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genomic instability status. The buccal mucosa is a stratified squamous epithelial layer that allows 
a minimally invasive approach towards cellular collection. In light of the fact that 90% of 
cancers are epithelial in origin (240), buccal cell utilisation has great epidemiological potential 
both as a non-invasive means for genotoxic assessment and in identifying potential biomarkers 
for future disease assessment. Furthermore, keratinocytes are big cells with abundant cytoplasm 
(237) and they can be studied without the need of a cell culture, which makes this test both 
simple and cheap. For all of these reasons, cells derived from oral mucosa can be used to monitor 
early genotoxic events caused by ingestion or inhalation of carcinogens (241); the capability for 
test performance also makes it ideal for the study of whole populations with increased risk or 
susceptible to cytotoxic damage by means of MN detection (187). The MN assay can also be 
used for epidemiologic studies with life style impact, occupational exposure, nutrition, among 
others (185,233,242). 
 
Also, Bolognesi et al. have demonstrated the importance of MN test in buccal cells in many 
lesions (243). Recently, Souza et al. demonstrated the importance of MN in buccal mucosa cells 
from women submitted to chemotherapy after mastectomy for breast cancer, as 
cytogenetic biomonitoring (244). The evaluation of MN number in buccal mucosa cells shows 
genomic instability caused by malignant tumour in somatic cells of humans (245). 
 
The correlation between the genome instability in two different tissues, e.g. lymphocytes and 
exfoliated buccal cells, might provide a clue for the use of buccal MN as a marker of cancer risk. 
In the present study, analysis of MN frequencies in buccal cells from patients having SCC 
revealed an increased chromosomal instability, similar to the ones in the lymphocytes, although 
the extent of damage varied between two tissues, thus mean that similar genotoxic events may 
cause MN occurrence in both tissues (246). The comprehensive MN assay, approach both in 
lymphocytes (247) and buccal cells, has increasingly been adapted for the last years (248,249). 
Goodson et al. noted 85 examples of environmental chemicals that disrupted key pathways in 
carcinogenesis, designated as “hallmarks of cancer” (223). Those hallmarks include 
hyperproliferative signalling, insensitivity to growth-factor signals, evasion of apoptosis, 
sustained angiogenesis, genomic instability, and mutation, promotion of inflammation, and 
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dysregulation of metabolism. Individual chemicals in mixtures, such as tobacco smoke and tar-
based vaginal sanitary products, accumulate in cells and tissues and activate important 
carcinogenic pathways (223).  
The DNA damages observed in BEC and PBL of patients with cervical lesion may be due to 
genomic instability, but environmental and other co-carcinogenic factor influences cannot be 
excluded. 
Since many papers have demonstrated the frequency of MN in cervical cells of patients with 
cervical lesions (198,199,200) the originality of this study comes from the evaluation of such 
biomarkers in two different tissues, in surrogate tissues. 
Furthermore, the results of this study are in line with recent data that emphasise the role of 
elevated MN frequency as a biomarker of cancer risk (173,250,251,252). Increased levels of MN 
are indicative of defects in DNA repair and chromosome segregation, which can result in the 
generation of daughter cells with altered genes or the deregulation of gene expression that 
eventually leads to the evolution of the chromosome instability phenotype observed in cancer 
(14,15). 
In the present study, the MN assay was used simultaneously to detect baseline genetic damage 
both in lymphocytes and buccal cells in patients with cervical lesions. Originality of this study 
comes from the assessment of MN frequencies in two different surrogate tissues of patients with 
LSIL, HSIL and SCC of cervix, also from the assessment of other nuclear anomalies such as 
NPBs and NBUDs.  
 
The determination of MN frequency in PBL and BEC as surrogate tissues, can represent an 
additional marker for evaluation of genomic instability in patients with different grade of 
cervical lesions.  
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7. CONCLUSION 
 
Based on the results gained from this study, regarding the frequency of MN in BEC, PBL, as 
well as NPB and NBUD in PBL, in patients with LSIL, HSIL, SCC and control group, was 
concluded: 
1. Highly statistically significant frequency of MN in PBL between patients with SCC 
and patients with LSIL, HSIL and control group as well as between HSIL group and 
control group; increased frequency of MN, but not statistically significant between 
LSIL group and control group. 
 
2. Highly statistically significant frequency of MN in BEC between patients with SCC 
and patients with LSIL, HSIL and control group; progressive increased frequency of 
MN in patients with LSIL and HSIL groups compare to control. 
 
3. A highly statistically significant frequency of NPB and NBUD in PBL was shown 
also between patients with SCC and patients with LSIL, HSIL and control group as 
well as progressive increased frequency in LSIL, HSIL group compare to control 
group. 
 
4. Significantly strong positive correlation between MN in BEC and MN in PBL in 
patients with different grade of cervical squamous lesions. 
 
 
 
To our knowledge, for the first time, the MN assay was used simultaneously to detect 
baseline genetic damage both in lymphocytes and buccal cells in patients with cervical 
squamous lesions. These results confirmed that pathological status of the subjects had a 
significant effect on the increase of MN frequency. 
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It seems that MN frequencies in PBL and BEC and frequencies of NPB and NBUD in 
lymphocytes might be sensitive-markers to detect genomic instability in case of LSIL, 
HSIL and SCC of cervix. To our knowledge, also, this is the first study evaluating the 
correlation between MN in BEC and MN in PBL in patients with LSIL, HSIL and SCC. 
Although larger studies are needed, our data demonstrate the predictive value of MN, 
NPB and NBUD as biomarkers of genomic instability for evaluation of risk level of 
cancer diseases. Since we have found the increased frequencies of such biomarkers even 
in precancerous condition, clinically, the ability to identify high-risk subgroups is 
imperative, such individuals might benefit from early detection and prevention programs. 
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8. ABSTRACT  
 
The frequency of micronuclei in peripheral blood lymphocytes and buccal exfoliated cells 
in women with cervical cancer, Goneta Gashi, 2018 
 
A biological marker is an important aspect of the diagnosis, prognosis and risk assessment of a 
disease. The aim of this study was the evaluation of genomic instability in patients with cervical 
lesions. 
The genetic damages were investigated  in 100 subjects: patients with low grade squamous 
intraepithelial lesions (LSIL; n=20), patients with high grade squamous intraepithelial lesions 
(HSIL; n=20) patients with invasive squamous cervical cancer (SCC; n=20) and healthy women 
(n=20) with cytokinesis-block micronucleus cytome (CBMN cyt) assay in peripheral blood 
lymphocytes (PBL), and buccal micronucleus assay in buccal exfoliated cells (BEC), in order to 
assess the frequency of micronucleus (MN) in PBL and frequency of MN in BEC as well as the 
frequency of other nuclear anomalies such as nucleoplasmic bridges (NPBs) and nuclear bunds 
(NBUDs) in PBL. 
The frequency of MN in BEC, MN in PBL, NPB in PBL and NBUD in PBL were significantly 
higher (p< 0.001), in patients compared to control. Pearson’s correlation revealed a statistically 
significant strong positive correlation between variables in patients groups (p<0.001).  
Although larger studies are needed, our data support the predictive value of MN, NPB and 
NBUD as biomarkers of genomic instability for evaluation of risk level of cervical cancer 
diseases.  
 
Keywords: cytokinesis-block micronucleus cytome assay, micronucleus, cervical lesion, 
genomic instability, the buccal micronucleus assay. 
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9. SAŽETAK (ABSTRACT IN CROATIAN) 
 
Biološki marker predstavlja važan dio u dijagnostici, prognozi i procjeni rizika za određenu 
bolest. Cilj rada bio je procijeniti genomsku nestabilnost kod pacijentica sa cervikalnim lezijama. 
Genetska oštećenja su istraživana kod 100 žena /20 bolesnica sa skvamoznom intraepitelnom 
lezijom niskog stupnja (LSIL), 40 bolesnica sa skvamoznom intraepitelnom lezijom visokog 
stupnja (HSIL), 20 bolesnica sa invazivnim rakom vrata maternice (SCC), 20 žena bez bolesti, 
kao kontrolna skupina/, primjenom testa blokiranja citokineze mikronuklearnog citoma 
(engl.cytokinesis-block micronucleus cytome - CBMN cyt) na limfocitima periferne krvi (PBL) 
te bukalnog mikronuklearnog testa na eksfoliranim bukalnim stanicama (BEC). U radu se takođe 
istražila učestalost drugih nuklearnih anomalija kao što s nukleoplazmatski mostovi (NPB) i 
nuklearni pupoljci (NBUD) u PBL. 
Učestalost MN u BEC, MN u PBL, NPB u PBL i NBUD u PBL značajno je viša (p< 0.001) kod 
bolesnica nego u kontroloj skupini zdravih žena. Pearsonova korelacija upućuje na jaku 
pozitivnu povezanost između varijabli u skupinama pacijentica, što je statistički značajno 
(p<0.001). 
Premda je potrebno daljnje istraživanje na većem uzorku, naši rezultati podržavaju mišljenje da 
prediktivne vrijednosti MN, NPB i NBUD predstavljaju biomarkere genomske nestabilnosti za 
procjenu razine rizika i za nastanak raka vrata maternice.  
Ključne riječi: cytokinesis-block micronucleus cytome test, mikronukleus, cervikalna lezija, 
genomska nestabilnost, bukalni mikronuklearni test. 
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